Result of AGM
Bioventix PLC announced that all resolutions were passed at its Annual General Meeting held on December 4, 2025. The company, which specializes in developing and supplying high-affinity monoclonal antibodies for clinical diagnostics, confirmed the successful outcome of its shareholder meeting. This positive procedural development suggests continued shareholder support for the company's strategic direction and operations.
Select text to share a quote on X · sign in to keep highlights & notes in your BVXP notes
Bioventix PLC (AIM: BVXP) a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that at its Annual General Meeting held today, all resolutions put to shareholders were duly passed.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.